Optipharm.CO.LTD Cash Flow Conversion Efficiency

Latest as of June 2026: 0.037x

Optipharm.CO.LTD cash flow conversion efficiency. Based on the latest financial reports, Optipharm.CO.LTD (153710) has a cash flow conversion efficiency ratio of 0.037x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩905.29 Million ≈ $613.51K USD) by net assets (₩24.55 Billion ≈ $16.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Optipharm.CO.LTD (2015–2025)

Cash flow conversion efficiency of Optipharm.CO.LTD from 2015 to 2025. This chart illustrates how Optipharm.CO.LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Optipharm.CO.LTD stock quote for real-time trading data and today's change.

Optipharm.CO.LTD Cash Flow Conversion Ratio Explained

Optipharm.CO.LTD cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Optipharm.CO.LTD Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Optipharm.CO.LTD ranked by their cash flow conversion efficiency. Also see 153710 market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Woongjin Thinkbig Co Ltd KO:095720	0.087x
Componenta Corp HE:CTH1V	0.115x
UBIVELOX Inc KQ:089850	-0.048x
Tune Protect Group Bhd KLSE:5230	0.004x
Base Carbon Inc. NEO:BCBN	-0.004x
Unibios Holdings S.A AT:BIOSK	0.017x
Erbosan Erciyas Boru Sanayi Ve Ticaret AS IS:ERBOS	0.013x
Ekso Bionics Holdings Inc NASDAQ:EKSO	-0.370x

Annual Cash Flow Conversion Efficiency for Optipharm.CO.LTD (2015–2025)

The table below shows the annual cash flow conversion efficiency of Optipharm.CO.LTD from 2015 to 2025. Review 153710 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.40 Billion ≈ $17.21 Million	₩-1.55 Billion ≈ $-1.05 Million	-0.061x	-180.98%
2024-12-31	₩27.34 Billion ≈ $18.52 Million	₩-595.50 Million ≈ $-403.56K	-0.022x	+68.20%
2023-12-31	₩25.14 Billion ≈ $17.04 Million	₩-1.72 Billion ≈ $-1.17 Million	-0.069x	+18.34%
2022-12-31	₩29.01 Billion ≈ $19.66 Million	₩-2.43 Billion ≈ $-1.65 Million	-0.084x	-31.87%
2021-12-31	₩30.96 Billion ≈ $20.98 Million	₩-1.97 Billion ≈ $-1.33 Million	-0.064x	-32.95%
2020-12-31	₩33.78 Billion ≈ $22.89 Million	₩-1.62 Billion ≈ $-1.10 Million	-0.048x	-480.82%
2019-12-31	₩35.61 Billion ≈ $24.13 Million	₩447.47 Million ≈ $303.24K	0.013x	-62.99%
2018-12-31	₩35.44 Billion ≈ $24.02 Million	₩1.20 Billion ≈ $815.47K	0.034x	+66.43%
2017-12-31	₩12.79 Billion ≈ $8.67 Million	₩260.86 Million ≈ $176.78K	0.020x	-68.03%
2016-12-31	₩13.50 Billion ≈ $9.15 Million	₩861.36 Million ≈ $583.73K	0.064x	+136.47%
2015-12-31	₩4.30 Billion ≈ $2.91 Million	₩-751.51 Million ≈ $-509.29K	-0.175x	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$41.61 Million

₩61.39 Billion KRW

Market Cap Rank

#22373 Global

#1426 in Korea

Share Price

₩4185.00

Change (1 day)

-0.71%

52-Week Range

₩4185.00 - ₩6200.00

All Time High

₩28900.00